// App-Quantinova.ai

: Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed By Autologous Stem Cell Transplantation for AL Amyloidosis: Long Term Follow-up Analysis

Researchers

Presenter

  • Vishal K Gupta

Principal Investigators

  • Dina Brauneis

  • Anthony C Shelton

  • Karen Quillen

  • John Mark Sloan

  • Vaishali Sanchorawala

Medical Centers

  • Boston Medical Center, Boston, MA

  • Section of Hematology & Medical Oncology, Department of Medicine, Boston University School of Medicine and Boston Medical Center, Boston, MA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Endocrine/metabolic Diseases (ME)

Disease

  • AL Amyloidosis

  • Albuminuria

Biomarkers

  • B-type natriuretic peptide

  • Cluster of Differentiation 34

  • Creatinine

  • N-terminal pro b-type natriuretic peptide

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Bortezomib

  • Melphalan

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT01083316

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved